Anticalin proteins are low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins found in blood plasma and other bodily fluids.

The company primarily focuses on development of two drug candidates, including PRS-080 designed to target hepcidin for the treatment of functional iron deficiency in anemic patients with chronic kidney disease or in end-stage renal disease patients requiring dialysis; and PRS-060, a drug candidate that binds to the IL-4RA receptor alpha-chain, which is used for the treatment of asthma and other inflammatory diseases.

The company is also developing PRS-110, a monovalent antagonist that is used for the treatment of various types of cancers, including renal, gastric, and lung carcinomas, as well as central nervous system tumors and sarcomas; and PRS-300series of Anticalin proteins in immuno-oncology.

Pieris Pharmaceuticals is based in Germany.

CEO: Stephen S. Yoder

CDO: Louis Matis